Drug Profile


Alternative Names: Cytotropic heterogeneous molecular lipids

Latest Information Update: 27 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glory Pharmaceuticals
  • Developer Glory Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Saturated fatty acids; Triterpenes; Unsaturated fatty acids; Vitamins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cancer
  • Phase II Liver cancer

Most Recent Events

  • 27 Aug 2015 Development in Cancer is ongoing in USA
  • 27 Aug 2015 The process for obtaining manufacturing approval in China is ongoing
  • 27 Aug 2012 Investigation in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top